Pfizer Drug Poised to Disrupt Weight Loss Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Source: NASDAQ.COM
- Increased Market Competition: The dominance of Novo Nordisk and Eli Lilly in the weight loss drug market is threatened as Pfizer's PF-08653944 shows a weight loss of 10% to 12% in Phase 2 trials, potentially altering existing pricing power.
- Dosing Advantage: Pfizer's PF-08653944 requires only monthly injections, unlike Novo's Wegovy and Lilly's Zepbound, which necessitate weekly doses; this dosing difference could attract more patients and impact market share.
- Revenue Outlook Decline: Novo Nordisk anticipates a revenue drop of 5% to 13% in 2025 due to increased competition and pricing pressures, particularly with Pfizer's drug poised for market entry.
- Future Trial Plans: Pfizer plans over 20 anti-obesity trials in 2026, including 10 Phase 3 trials for PF-08653944, which could further intensify market competition and compress profit margins.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 26.670
Low
24.00
Averages
28.56
High
35.00
Current: 26.670
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CureVac Sues Moderna Over Patent Infringement
- Patent Infringement Lawsuit: German biotech firm CureVac filed a lawsuit against Moderna in Delaware federal court, alleging that Moderna's COVID-19 vaccine Spikevax infringes CureVac's patents related to messenger RNA technology, seeking royalties from Spikevax sales, highlighting the intensifying patent disputes in the COVID-19 vaccine market.
- Technology Copying Allegations: CureVac claims that Moderna copied its technology for stabilizing fragile mRNA, and if proven, this could significantly impact Moderna's vaccine sales and market position, potentially leading to substantial damages.
- Intensifying Industry Competition: BioNTech, which acquired CureVac last year, filed a separate patent lawsuit against Moderna in February regarding its next-generation mNEXSPIKE COVID-19 shot, indicating escalating competition among biotech firms, particularly in the COVID-19 vaccine sector.
- Ongoing Legal Battles: Moderna previously sued Pfizer and BioNTech in 2022 for patent infringement over its Comirnaty vaccine, and the current lawsuit is part of a broader trend of biotech companies seeking a share of the tens of billions in revenue generated from COVID-19 vaccine sales, reflecting the ongoing legal struggles within the industry.
See More
BridgeBio Shares Rise on Patent Settlement Indications
- Patent Settlement Progress: BridgeBio (BBIO) shares rose 2.9% following court filings indicating a settlement between Pfizer (PFE) and Dexcel in a patent lawsuit concerning Pfizer's Vyndamax drug, which could positively impact BBIO.
- Market Expectation Shift: Barclays analyst Eliana Merle noted that investors might view the settlement between Pfizer and Dexcel as a positive signal, although specific details regarding the settlement date and potential agreements with other defendants remain undisclosed, improving market sentiment towards BBIO.
- Future Outlook: Barclays anticipates that if the settlement proceeds smoothly, a generic version of Vyndamax could enter the market by 2031, potentially benefiting BBIO's Attruby drug, which is similar to Vyndamax.
- Stock Price Volatility Prediction: Analysts believe that if Pfizer settles or wins, BBIO shares could rise by 30-40%; conversely, if Pfizer loses, shares might drop by 20-30%, indicating the market's high sensitivity to this event.
See More
Eliquis to Launch on Mark Cuban Cost Plus Drug Website
- Platform Launch: Bristol Myers Squibb and Pfizer's blockbuster blood thinner Eliquis will launch on the Mark Cuban Cost Plus Drug website on April 27, marking a significant step towards drug pricing transparency by both companies.
- Pricing Strategy: A 30-day supply of Eliquis will cost $345, matching the existing price of Bristol and Pfizer's Eliquis Direct-to-Patient program, aimed at enhancing market competitiveness by reducing patient burden.
- Broad Indications: Eliquis is approved to reduce the risk of stroke and blood clots in individuals with atrial fibrillation, as well as for deep vein thrombosis and pulmonary embolism, highlighting its importance in cardiovascular disease management.
- Market Outlook: Despite a rating downgrade for Bristol Myers Squibb's outlook, the strong demand for Eliquis may lead to unexpectedly positive results for Pfizer in upcoming earnings reports.
See More
Eli Lilly and Novo Nordisk Competition Intensifies
- Prescription Competition: Eli Lilly's GLP-1 weight-loss drug garnered only 3,770 prescriptions in its first week, while Novo Nordisk's Wegovy oral version achieved 18,410, indicating a slower market acceptance for Lilly's new launch that could hinder future sales growth.
- Analyst Rating Upgrade: JPMorgan initiated coverage on Hims & Hers Health with an overweight rating and a price target of $35, which, although not significantly above the current price, led to a 5.8% stock increase, reflecting optimistic market sentiment regarding the company's potential.
- Free Therapy Initiative: Regeneron introduced a new gene therapy aimed at restoring hearing in children with specific causes of deafness, partnering with the White House to provide this treatment for free; despite a 3% drop in stock price, this initiative may enhance the company's reputation and attract social attention.
- Market Trend Shift: Hims & Hers is seen as ahead of the peptide drug trend due to its California facility, with JPMorgan expecting the FDA to approve 12 peptides for mass compounding, potentially opening new growth avenues for the company and highlighting strong market demand for peptide therapies.
See More
Bristol Myers Squibb-Pfizer Alliance Partners with Cost Plus Drugs for Eliquis Access
- Expanded Access Channels: The Bristol Myers Squibb-Pfizer Alliance has partnered with Cost Plus Drugs to offer Eliquis on CostPlusDrugs.com starting April 27, 2026, allowing cash-paying patients to purchase the medication for $345, significantly lowering access costs and enhancing patient availability.
- Market Demand Response: This collaboration addresses the strong market demand for Eliquis, with Cost Plus Drugs co-founder Mark Cuban emphasizing that patients should not have to guess medication prices, thereby providing a clearer and more direct access route that empowers patients.
- Healthcare Cost Savings: Eliquis is projected to save an estimated $3 billion in healthcare costs for every 100,000 patients treated, reducing hospitalization and rehabilitation needs, highlighting the drug's strategic importance in improving patient health and lowering overall healthcare expenditures.
- Continuation of Patient Support Programs: This partnership follows the 2025 launch of the Eliquis 360 Support program, further solidifying the BMS-Pfizer Alliance's commitment to patient resource support and aiming to enhance patient medication experiences through diversified access channels.
See More
CDC Blocks Publication of COVID Vaccine Study Despite Review
- Publication Blocked: The CDC has blocked the publication of a report on COVID-19 vaccines reducing hospitalization risk after it passed scientific review, a highly unusual action that indicates internal sensitivity regarding vaccine efficacy research.
- Methodology Controversy: HHS spokesperson noted that CDC leadership routinely flags concerns about MMWR papers, particularly regarding methodology, and the current study's observational method has raised doubts, potentially undermining public trust in vaccines.
- Vaccine Effectiveness Comparison: While the COVID vaccine study is on hold, a flu vaccine effectiveness study using the same methodology was published in March, highlighting inconsistencies in CDC's handling of vaccine research that may raise public skepticism about vaccine policies.
- Policy Changes Impact: Under HHS Secretary RFK Jr., the CDC has removed vaccine recommendations for healthy children and pregnant women and paused federal funding for mRNA vaccine research, a series of policy shifts that could affect vaccination rates and public health strategies.
See More
CureVac Sues Moderna Over Patent Infringement
- Patent Infringement Lawsuit: German biotech firm CureVac filed a lawsuit against Moderna in Delaware federal court, alleging that Moderna's COVID-19 vaccine Spikevax infringes CureVac's patents related to messenger RNA technology, seeking royalties from Spikevax sales, highlighting the intensifying patent disputes in the COVID-19 vaccine market.
- Technology Copying Allegations: CureVac claims that Moderna copied its technology for stabilizing fragile mRNA, and if proven, this could significantly impact Moderna's vaccine sales and market position, potentially leading to substantial damages.
- Intensifying Industry Competition: BioNTech, which acquired CureVac last year, filed a separate patent lawsuit against Moderna in February regarding its next-generation mNEXSPIKE COVID-19 shot, indicating escalating competition among biotech firms, particularly in the COVID-19 vaccine sector.
- Ongoing Legal Battles: Moderna previously sued Pfizer and BioNTech in 2022 for patent infringement over its Comirnaty vaccine, and the current lawsuit is part of a broader trend of biotech companies seeking a share of the tens of billions in revenue generated from COVID-19 vaccine sales, reflecting the ongoing legal struggles within the industry.
See More
BridgeBio Shares Rise on Patent Settlement Indications
- Patent Settlement Progress: BridgeBio (BBIO) shares rose 2.9% following court filings indicating a settlement between Pfizer (PFE) and Dexcel in a patent lawsuit concerning Pfizer's Vyndamax drug, which could positively impact BBIO.
- Market Expectation Shift: Barclays analyst Eliana Merle noted that investors might view the settlement between Pfizer and Dexcel as a positive signal, although specific details regarding the settlement date and potential agreements with other defendants remain undisclosed, improving market sentiment towards BBIO.
- Future Outlook: Barclays anticipates that if the settlement proceeds smoothly, a generic version of Vyndamax could enter the market by 2031, potentially benefiting BBIO's Attruby drug, which is similar to Vyndamax.
- Stock Price Volatility Prediction: Analysts believe that if Pfizer settles or wins, BBIO shares could rise by 30-40%; conversely, if Pfizer loses, shares might drop by 20-30%, indicating the market's high sensitivity to this event.
See More
Eliquis to Launch on Mark Cuban Cost Plus Drug Website
- Platform Launch: Bristol Myers Squibb and Pfizer's blockbuster blood thinner Eliquis will launch on the Mark Cuban Cost Plus Drug website on April 27, marking a significant step towards drug pricing transparency by both companies.
- Pricing Strategy: A 30-day supply of Eliquis will cost $345, matching the existing price of Bristol and Pfizer's Eliquis Direct-to-Patient program, aimed at enhancing market competitiveness by reducing patient burden.
- Broad Indications: Eliquis is approved to reduce the risk of stroke and blood clots in individuals with atrial fibrillation, as well as for deep vein thrombosis and pulmonary embolism, highlighting its importance in cardiovascular disease management.
- Market Outlook: Despite a rating downgrade for Bristol Myers Squibb's outlook, the strong demand for Eliquis may lead to unexpectedly positive results for Pfizer in upcoming earnings reports.
See More
Eli Lilly and Novo Nordisk Competition Intensifies
- Prescription Competition: Eli Lilly's GLP-1 weight-loss drug garnered only 3,770 prescriptions in its first week, while Novo Nordisk's Wegovy oral version achieved 18,410, indicating a slower market acceptance for Lilly's new launch that could hinder future sales growth.
- Analyst Rating Upgrade: JPMorgan initiated coverage on Hims & Hers Health with an overweight rating and a price target of $35, which, although not significantly above the current price, led to a 5.8% stock increase, reflecting optimistic market sentiment regarding the company's potential.
- Free Therapy Initiative: Regeneron introduced a new gene therapy aimed at restoring hearing in children with specific causes of deafness, partnering with the White House to provide this treatment for free; despite a 3% drop in stock price, this initiative may enhance the company's reputation and attract social attention.
- Market Trend Shift: Hims & Hers is seen as ahead of the peptide drug trend due to its California facility, with JPMorgan expecting the FDA to approve 12 peptides for mass compounding, potentially opening new growth avenues for the company and highlighting strong market demand for peptide therapies.
See More
Bristol Myers Squibb-Pfizer Alliance Partners with Cost Plus Drugs for Eliquis Access
- Expanded Access Channels: The Bristol Myers Squibb-Pfizer Alliance has partnered with Cost Plus Drugs to offer Eliquis on CostPlusDrugs.com starting April 27, 2026, allowing cash-paying patients to purchase the medication for $345, significantly lowering access costs and enhancing patient availability.
- Market Demand Response: This collaboration addresses the strong market demand for Eliquis, with Cost Plus Drugs co-founder Mark Cuban emphasizing that patients should not have to guess medication prices, thereby providing a clearer and more direct access route that empowers patients.
- Healthcare Cost Savings: Eliquis is projected to save an estimated $3 billion in healthcare costs for every 100,000 patients treated, reducing hospitalization and rehabilitation needs, highlighting the drug's strategic importance in improving patient health and lowering overall healthcare expenditures.
- Continuation of Patient Support Programs: This partnership follows the 2025 launch of the Eliquis 360 Support program, further solidifying the BMS-Pfizer Alliance's commitment to patient resource support and aiming to enhance patient medication experiences through diversified access channels.
See More
CDC Blocks Publication of COVID Vaccine Study Despite Review
- Publication Blocked: The CDC has blocked the publication of a report on COVID-19 vaccines reducing hospitalization risk after it passed scientific review, a highly unusual action that indicates internal sensitivity regarding vaccine efficacy research.
- Methodology Controversy: HHS spokesperson noted that CDC leadership routinely flags concerns about MMWR papers, particularly regarding methodology, and the current study's observational method has raised doubts, potentially undermining public trust in vaccines.
- Vaccine Effectiveness Comparison: While the COVID vaccine study is on hold, a flu vaccine effectiveness study using the same methodology was published in March, highlighting inconsistencies in CDC's handling of vaccine research that may raise public skepticism about vaccine policies.
- Policy Changes Impact: Under HHS Secretary RFK Jr., the CDC has removed vaccine recommendations for healthy children and pregnant women and paused federal funding for mRNA vaccine research, a series of policy shifts that could affect vaccination rates and public health strategies.
See More
